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Early detection of a mutated p53 gene is thought to provide useful information in a wide range of human
tumors. The aim of this study was to identify the role of the p53 gene in transitional cell carcinoma of
the urinary tract. From March 1992 to July 2003, 75 patients (54 men and 21 women) with a mean age
of 66.85 years and pathologically diagnosed transitional cell carcinoma were enrolled in this study. Fifty-
eight patients had bladder cancer, eight had ureteral cancer, and nine had renal–pelvic cancer. Rapid
screening for mutation of the p53 gene was performed using polymerase chain reaction (PCR), single-
strand conformation polymorphism (SSCP), and sequencing analysis. Primer sets were designed to amplify
fragments within exons 4, 5, 6, 7, and 8 of the p53 gene. Pathology classified 37 tumors as low grade and
38 as high grade. Tumor stage was pT1 or less in 29 patients and at least pT2 in 46 patients. Of the 75
patients in this study, 47 (62.7%) had a p53 mutation. Of the patients with a p53 mutation, 33 (70.2%) had
invasive tumors. Invasive tumors were associated with p53 mutation (p < 0.05). Noted in 20 patients
(26.7%), exon 4 was the most common site of the mutation. Of the patients with exon 4 mutations,
15 (75%) had invasive tumors and nine (45%) had high-grade tumors. Additionally, among the 20 patients
with a common polymorphism at codon 72, 16 (80%) had invasive tumors and 14 (70%) had high-grade
tumors. In this study, 62.7% of patients with transitional cell carcinoma had a p53 mutation, suggesting
that the p53 gene mutation may be used as a marker of transitional cell carcinoma. Invasive tumors are
more likely to have a p53 gene mutation. A simple analysis of the p53 gene using PCR/SSCP is suitable
for screening for p53 abnormalities in transitional cell carcinoma. The relationship between cancer risk
and the codon 72 polymorphism of exon 4 needs further investigation.
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Oncogenic activity or loss of tumor suppressor gene func-
tion resulting from genetic alterations, such as mutation,
insertion, or deletion, is prevalent in tumor cells and ulti-
mately causes abnormal gene expression. The p53 gene is a
well-characterized tumor suppressor gene and is the most
frequently altered gene in human cancer. Mutations in p53
occur in approximately 60% of carcinomas. The gene is
located in band p13.1 of chromosome 17 and encodes a
53-kd nuclear phosphoprotein involved in the control of
cellular proliferation [1–3]. The p53 protein functions as a
sequence-specific transcription factor and is important for
the regulation of genes that promote growth arrest or
apoptosis in response to cellular stress [4,5].
The role of the p53 gene in colon cancer has been studied
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in great detail. Mutation is most likely within the highly
conserved region comprising exons 4–8 [6]. p53 modulates
responsiveness to different drugs or treatments [7].
Polymorphism in codon 72 of exon 4 of the p53 gene is
associated with the malignancy of colorectal cancer in
Taiwanese patients [8].
Transitional cell carcinoma (TCC) is the fifth most com-
mon solid malignancy in the USA. After prostate cancer,
TCC of the bladder is the second most common malignancy
of the genitourinary tract, and annually accounts for about
54,000 new diagnoses and more than 12,000 deaths in the
USA alone [9]. In Taiwan, the incidence of bladder cancer is
2.29/100,000 and accounts for about 400 deaths (1.91/
100,000) annually [10]. Certain genitourinary cancers (testis
cancer, pheochromocytoma, and Wilms tumors) do not
commonly manifest p53 mutations, whereas others (bladder
and prostate cancers) are frequently associated with p53
alterations [11]. Therefore, TCC of the urinary tract provides
a good model for understanding the genetic alteration in tu-
mors because the histologic progression of this tumor is corre-
lated with p53 gene mutation [12]. This study serves to clarify
the role of p53 mutations in Taiwanese patients with TCC.
MATERIALS AND METHODS
Tissue samples
From March 1992 to July 2003, specimens were collected
from patients with TCC of the bladder, ureter, or renal
pelvis, as diagnosed by pathology, at Kaohsiung Medical
University Hospital. Patients with a benign diagnosis or
with incomplete exon 4–8 analysis data were excluded from
the study. All fresh tissue samples were snap-frozen
immediately and stored at –80°C until further use.
Histopathology, tumor grades and stages
Standard histopathologic criteria were used to classify tumor
grade and stage for each type of cancer. All tumors were
graded in accordance with the World Health Organization
system [13]. Clinical and pathologic classifications were
determined in accordance with the American Joint Committee
on Cancer/International Union Against Cancer TNM 1997
criteria [14]. In this system, grade 1 and 2 tumors are defined
as low grade and grade 3 and 4 tumors are defined as high
grade; tumors of pT1 or less are classified as superficial and
those of at least pT2 are classified as invasive.
DNA extraction from tumor tissue
DNA was extracted using the DNeasyTM Tissue Kit (Qiagen,
Valencia, CA, USA) and following the manufacturer’s rec-
ommendations. The tumor tissue was digested with
0.5 mg/mL proteinase K in 400 µL cell-lysis solution for
24 hours at 55°C until the tissue was completely lysed.
200 µL absolute ethanol were added and the mixture
transferred into the DNeasy mini column and centrifuged
for 1 minute at 8,000 rpm. The DNeasy mini column was
washed with 500 µL washing buffer and centrifuged again
for 1 minute at 8,000 rpm. Finally, the DNA was eluted into
a clean 1.5-mL microcentrifuge tube. The concentration and
purity of DNA were determined by measuring the QD at
260 and 280 nm using a spectrophotometer.
Polymerase chain reaction single-strand
conformational polymorphism analysis
The highly conserved regions of the p53 gene, exons 4–8,
were amplified separately using various intronic oligo-
nucleotide primers (Table 1). The polymerase chain reaction
(PCR) was performed using the “hot-start” technique in a
final volume of 25 µL reaction buffer containing 50 mM KCl,
1.5 mM MgCl2, 10 mM Tris-HCl (pH 9.0 at room tem-
perature), 2 µM EDTA, 0.1 mM dithiothreitol, 1% glycerol,
200 µM each of dATP, dCTP, and dTTP, 50 µM dGTP, 150
µM 7-deaza-dGTP, 10 pmole of each primer, 1.5 U Taq
polymerase, and 60 ng genomic DNA in a 0.5-mL
polypropylene microtube. After a 35-cycle amplification
process (including denaturation for 30 seconds at 94°C,
annealing for 30 seconds at 55°C, and extension for 30
seconds at 72°C), 8 µL of amplicons mixed with 8 µL of 2×
sample buffer (2× TBE, 0.1% bromophenol blue, 0.1% xylene
cyanol, and 10% Ficoll 400) were separated on a 2.5%
nondenaturing agarose gel (Amresco, Solon, OH, USA) and
visualized using ethidium bromide.
For single-strand conformation polymorphism (SSCP)
analysis, 4 µL of the PCR product was diluted in 4 µL
loading buffer, including 95% formamide, 20 mM ethylene-
diamine tetraacetic acid, 0.05% bromophenol blue, and
0.5 mL xylene cyanol, heated at 95°C for 3 minutes, and
cooled on ice before loading. The electrophoretic analysis
was then performed on a Genephor electrophoresis unit
(Amersham Pharmacia Biotech, Uppsala, Sweden) using
the manufacturer’s Genegel Excel 12.5/24 kit, at 5°C for 3–
4 hours at 25 mA, 15 W, and 200 V. Finally, the gels were
stained in a Hoefer Automated Gel Stainer (Amersham
Pharmacia Biotech) with the PlusOne DNA Silver Staining
Kit (Amersham Pharmacia Biotech).
DNA sequencing analysis
Sequence analysis was performed using the ABI PRISMTM
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310 Genetic Analyzer (Perkin-Elmer Applied Biosystems,
Foster City, CA, USA) and the original p53 PCR products.
PCR product purified using QIA Quick Purification
Columns (Qiagen, Hilden, Germany) was used in Taq cycle
sequencing with the Dye Terminator Cycle Sequencing
Ready Reaction Kit (ABI Prism, Perkin-Elmer Applied
Biosystems), following the manufacturer’s instructions. If
the presence of a gene mutation was not compatible between
SSCP and sequencing, the variant band was selected from
the gel and reamplified. To avoid false-positive results due
to polymerase errors, PCR products were tested again by
performing a new PCR, SSCP, and sequence analysis [15].
Statistical analysis
Statistical analysis was performed with SPSS version 10.0
(SPSS Inc, Chicago, IL, USA). The Chi-squared test was
used to describe the relationship between tumor grade and
gene mutation and the correlations among gene mutation,
tumor stage, and gender. The t test was used to analyze the
relationship between age and gene mutation. A p value of
0.05 or less was chosen as the level of statistical significance.
RESULTS
A total of 94 specimens were collected initially. Thirteen
specimens with a benign pathologic diagnosis and six
specimens with incomplete exon 4–8 analysis data were
excluded from the study. Therefore, 75 patients were
enrolled in the study, 54 men and 21 women, with a mean
age of 66.85 years (standard deviation, 10.78; range, 26–84
years). Fifty-eight patients had bladder cancer, eight had
ureteral cancer, and nine had renal–pelvic cancer. At the
time of pathologic diagnosis, 37 tumors were classified as
low grade and 38 as high grade. Tumors were superficial in
29 cases and invasive in 46 cases. PCR/SSCP results in exon
4 are shown in Figure 1. The results of direct sequencing
were compatible with those of SSCP analysis (Figure 2).
A total of 47 patients (62.7%) had p53 gene mutations.
Table 1. Polymerase chain reaction primers for p53 gene amplification
Exon Forward primer Reverse primer
4 5’-CAACGTTCTGGTAAGGACAA-3’ 5’-GCCTAAGGGTGAAGAGGAA-3’
5 5’-TCACTTGTGCCCTGACTT-3’ 5’-GAGGAATCAGAGGCCTGG-3
6 5’-GAGACGACAGGGCTGGTT-3’ 5’-GAGACCCCAGTTGCAAAC-3’
7 5’-CCAAGGCGCACTGGCCTC-3’ 5’-GCGGCAAGCAGAGGCTGG-3’
8 5’-CCTTACTGCCTCTTGCTTC-3’ 5’-TGAATCTGAGGCATAACT-3’
Figure 1. Polymerase chain reaction (PCR)/single-strand conformation
polymorphism (SSCP) analysis of exon 4 of the p53 gene in transitional
cell carcinoma tissue. Arrows indicate shifted bands (lanes 7 and 10); the
remaining bands represent the normal pattern.
M 1 2 3 4 5 6 7 8 9 10
Shifted bands
Among these, 33 were male and 14 were female. Twenty-
four patients with the p53 gene mutation had high-grade
tumors and 33 had invasive tumors. Since a significant
number of patients (33 of 47, 70.2%) had invasive tumors, it
suggests that p53 gene mutations are more common in more
highly invasive tumors. Although p53 gene mutations were
more prevalent in high-grade than low-grade tumors (24 vs
23), this finding did not reach statistical significance. This
indicates that tumor grade is not an important factor
associated with p53 gene mutation. p53 gene mutation was
more common in male than female patients (33 vs 14), but
this difference was not statistically significant, indicating
that sex is not a factor influencing p53 gene mutation. The t
test revealed no significant relationship between age and
p53 gene mutation. Correlations between p53 mutation and
possible factors are summarized in Table 2.
Among the 47 patients with p53 gene mutations, 20
(26.7%) had exon 4 mutations, five (6.7%) had exon 5
mutations, 12 (16%) had exon 6 mutations, 17 (22.7%) had
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exon 7 mutations, and nine (12%) had exon 8 mutations.
Furthermore, 14 TCC patients had a mutation in more than
one exon. Exon 4 was the most common site of mutation,
Table 2. Correlation among age, sex, tumor grade, tumor stage, and p53 gene mutation
p53 gene analysis Normal Mutated p
Age, yr 0.796*
Mean (range) 66.43 (44–84) 67.11 (26–84)
Gender 0.655†
Male 21 33
Female 7 14
Grade 0.929†
Low 14 23
High 14 24
Stage 0.041†‡
Superficial 15 14
Invasive 13 33
*t test; †Chi-squared test; ‡p < 0.05. Low grade = grades 1 and 2; high grade = grades 3 and 4; superficial stage = ≤ T1; invasive stage =
> T1.
Figure 2. DNA sequencing of exons
4 to 8. (A) Oblique arrow shows an
A→T point mutation at the second
base of codon 120, found in six cases.
(B) Frame shows a T→A point
mutation and an A deletion at the
second base of codon 224, found in
five cases.
B
 A
followed by exons 7, 6, 8, and 5, respectively. The mutation
sites in exon 4 are shown in Table 3.
Among the 20 patients with exon 4 mutations, 15 (75%)
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for further analysis.
We found that patients with invasive tumors were more
likely to have gene mutations, which is consistent with
previous reports [20,21]. However, unlike the relationship
between tumor stage and gene mutation, tumor grade was
not statistically associated with p53 gene mutation, a finding
that conflicts with our understanding of the likelihood of
p53 gene mutation in high-grade tumors [9,22].
There are three possible reasons for this discrepancy.
Surgical specimens were sent for pathologic diagnosis and
laboratory examination immediately and individually, so
whether the two tumor samples had the same grade clas-
sification was difficult to determine. If two samples had
different histopathologic characteristics, the malignancy
and tumor grade between pathologic diagnosis and our
laboratory data might have been different. Another reason
may be that most urothelial tumors in this study were from
patients with bladder cancer (58 patients), and most of the
bladder tumor samples were collected from transurethral
resection. In general, resection and coagulation were used
during surgery. As a consequence, some tissue, including
normal, high-grade, and low-grade tissue, may have been
destroyed, thereby influencing the results. The third
possibility is that our sample size was not large enough to
identify a correlation between tumor grade and p53 gene
mutation.
Some reports have stated that previous restrictions to
exons 5–8 may have slightly under-represented the true
incidence of p53 mutations in colorectal tumors [23]. Reports
had invasive tumors and five (25%) had superficial tumors
(p = 0.001), nine patients (45%) had high-grade tumors
and 11 (55%) had low-grade tumors (p = 0.09). Another
interesting finding was that 20 patients had a common
polymorphism at codon 72, of which six also had other
codon changes in exon 4; the changes in the other 14 existed
independently. Among the 20 patients with codon 72
polymorphisms, 16 (80%) had invasive tumors and 14
(70%) had high-grade tumors. Both of these findings were
statistically significant (p = 0.000 and 0.005, respectively),
indicating that patients with codon 72 polymorphisms are
more likely to have invasive or high-grade tumors.
DISCUSSION
In this study, PCR/SSCP analysis and sequencing of exons
4–8 demonstrated that 47 of 75 patients (62.7%) had p53
gene mutations. Of these, 33 (70.2%) had invasive tumors.
Our results reveal a higher mutation rate in invasive tumors
than previously reported [16,17]. Habuchi et al noted that
p53 mutations are undetectable in 30–50% of clinically
advanced urothelial cancers [18], and reported gene muta-
tion rates of 81% in invasive tumors [19]. These findings
suggest that the p53 gene mutation rate is relatively high in
patients with invasive tumors. Our findings also showed
that a higher p53 mutation rate is directly related to more
invasive tumors. However, to verify information about the
true mutation rate in the p53 gene, more subjects are needed
Table 3. Mutations in exon 4 of the p53 gene
Codon Codon change Nucleotide change Amino acid change Number of cases
36 CCG to CCA G to A Pro to Pro 1
49 GAT to TAT G to A Asp to Tyr 2
51 GAA to GAG A to G Glut to Glu 1
52 CAA to CAT A to T Gln to His 1
54 TTC to TTA C to A Phe to Leu 1
56 GAA to AAA G to A Glu to Lys 1
59 GGT to TGT G to T Gly to Cys 1
61 GAT to GGT A to G Asp to Gly 1
62 GAA to GAG A to G Glu to Glu 2
65 AGA to TGA A to T Arg to Ter 4
66 GTG to GATG Insert A Truncated 1
67 CCA to CCG A to G Pro to Pro 1
72 CGC to CCC G to C Arg to Pro 20
97 GTC to ATC G to A Val to Ile 1
101 AAA to AAAA Insert A Truncated 1
108 ACA to AACA Insert A Truncated 1
120 AAG to ATG A to T Lys to Met 1
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also indicate that most mutations develop in the core domain
of exons 4–9, with some mutations more significant than
others with respect to p53 function [24–27]. However, not
all studies were performed in the exon 4–9 region; some
reports only examined exons 5–8 [21,25,26]. In this study,
exon 4 of the p53 gene was the most common mutation site,
with multiple mutation sites including codons 36, 49, 51, 52,
54, 56, 59, 61, 62, 65, 66, 67, 97, 101, 108, and 120. Codon 72
abnormalities, thought to be normal polymorphisms, were
also noted.
Some researchers have described an analysis of exons 4–
9 of p53 gene mutations without stating the highest mutation
rate [24]. Other reports have indicated that exon 8 was the
most common mutation site in exon-5–8 analyses [22,25,26].
Among the 75 patients examined for exon 4–8 mutations in
this study, 20 (26.7%) had an exon 4 mutation. In addition,
almost 75% of patients with exon 4 mutations had invasive
tumors, indicating that they are closely related. For these
reasons, exon 4 mutation is worthy of further attention.
Among the 20 patients with codon 72 polymorphisms,
16 (80%) had invasive tumors and 14 (70%) had high-grade
tumors. Both of these findings reached statistical signifi-
cance. This suggests that codon 72 polymorphism is closely
related to invasive tumors and to high-grade tumors. It may
also imply a relationship between codon 72 polymorphism
and tumor progression, prognosis, and drug response.
CONCLUSION
In this study, 62.7% of TCC patients had a p53 mutation.
Additionally, being observed in 71.7% of the pT2 or greater
cases, invasive tumors were significantly more likely to
have a p53 gene mutation. In this study, age and sex were
not important risk factors associated with p53 gene mutation.
Although more high-grade than low-grade tumors had a
p53 gene mutation, it did not reach statistical significance.
These results indicate that p53 gene mutation may be used
as a marker of TCC. Simple analysis of the p53 gene using
PCR/SSCP is suitable for screening for p53 abnormalities in
TCC. The findings also suggest that the relationship between
cancer risk and codon 72 polymorphism in exon 4 needs
further investigation.
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